GSK Consumer Vet Scheske Sees OTC Potential In Biotech PepTcell's Portfolio
This article was originally published in The Tan Sheet
Executive Summary
PepTcell is in the late stages of developing a potential blockbuster cough suppressant, says Manfred Scheske, head of the U.K. biotech's consumer business
You may also be interested in...
Glaxo Veteran Directs Infirst’s Jump Into Differentiated OTCs
U.K. biotech SEEK launches infirst HEALTHCARE to focus on commercializing consumer products, while the firm’s pipeline continues developing. Former GlaxoSmithKline exec Manfred Scheske leads infirst as it prepares cough remedy and analgesic launches in multiple markets.
Glaxo Veteran Directs Infirst’s Jump Into Differentiated OTCs
U.K. biotech SEEK launches infirst HEALTHCARE to focus on commercializing consumer products, while the firm’s pipeline continues developing. Former GlaxoSmithKline exec Manfred Scheske leads infirst as it prepares cough remedy and analgesic launches in multiple markets.
Glaxo Veteran Directs Infirst’s Jump Into Differentiated OTCs
U.K. biotech SEEK launches infirst HEALTHCARE to focus on commercializing consumer products, while the firm’s pipeline continues developing. Former GlaxoSmithKline exec Manfred Scheske leads infirst as it prepares cough remedy and analgesic launches in multiple markets.